Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00883558 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus
A Phase 2 study of Diabetes Mellitus, Type 1, sponsored by Halozyme Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 8
- Study locations
NCT00883558 is a Phase 2 study of Diabetes Mellitus, Type 1 that has completed, run by Halozyme Therapeutics. The registered enrollment target is 48 participants, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (96% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT00883558, a Phase 2 study of Diabetes Mellitus, Type 1, has completed, sponsored by Halozyme Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 8
- Study locations
Study Summary
Insulin lispro is approved by the Food and Drug Administration (FDA) for the treatment of diabetes mellitus. Recombinant human hyaluronidase (rHuPH20) is approved by the FDA as an aid to the absorption and dispersion of other injectable drugs. In this study, rHuPH20 combined with a non-preserved (NP) formulation of regular human insulin (INSULIN-PH20 NP) will be compared to insulin lispro with respect to absorption and action of insulin.
Conditions Studied
Interventions
- DRUG Insulin glargine
- DRUG Insulin Lispro
- DRUG regular human insulin
- DRUG recombinant human hyaluronidase PH20
Study Locations (8)
Colorado
- Barbara Davis Center for Childhood Diabetes - Aurora
Florida
- Diabetes Research Institute - Miami
Michigan
- Henry Ford Health System - Detroit
Montana
- Mercury Street Medical - Butte
North Carolina
- UNC Diabetes Care Center/Highgate Specialty Center - Durham
Ohio
- Cleveland Clinic - Cleveland
Texas
- Texas Diabetes and Endocrinology - Austin
Washington
- West Olympia Internal Medicine - Olympia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00883558
The ClinicalTrials.gov registry entry for NCT00883558 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (96% lower). The listed sponsor is Halozyme Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 4 interventions - of which Insulin glargine is the first listed.
NCT00883558 reports 8 study locations spanning 8 distinct geographic areas - top geographies include Colorado, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT00883558 about?
NCT00883558 is a clinical study titled "Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus". Insulin lispro is approved by the Food and Drug Administration (FDA) for the treatment of diabetes mellitus. Recombinant human hyaluronidase (rHuPH20) is approved by the FDA as an aid to the absorption and dispersion of other injectable drugs. In this study, rHuPH20 combined with a non-preserved (NP...
What is the current status of trial NCT00883558?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2009-05. Estimated completion is 2010-04.
What conditions does trial NCT00883558 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT00883558?
The interventions under investigation include: Insulin glargine (DRUG), Insulin Lispro (DRUG), regular human insulin (DRUG), recombinant human hyaluronidase PH20 (DRUG).
Who is sponsoring clinical trial NCT00883558?
This trial is sponsored by Halozyme Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00883558 being conducted?
This trial has 8 study locations across Colorado, Florida, Michigan, Montana, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Islet Transplantation in Type 1 Diabetic Kidney Allograft
RECRUITING · Phase 2
-
Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes
RECRUITING · Phase 2
-
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
ACTIVE NOT RECRUITING · Phase 2
-
Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients
ACTIVE NOT RECRUITING · Phase 2
-
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
ACTIVE NOT RECRUITING · Phase 2
-
Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.